To include your compound in the COVID-19 Resource Center, submit it here.

Sarepta gains option to Duke's CRISPR tech for DMD

Duke University granted Sarepta Therapeutics Inc. (NASDAQ:SRPT) an option to gain exclusive rights to IP and technology developed in Charles Gersbach's

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE